FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS
Links shared publicly online about this topic.
- 1,093total visits
FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS
Genzyme Corporation announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease.
View full resource at news-medical.net
Tags: Multiple Sclerosis, Disease and Condition, Drug, FDA, Genzyme
Most Recently Shared on June 15, 2010 at 6:12 am By:
FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS: Genzyme Corporation announced t... http://bit.ly/a2yIsx
Advertisement
